Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs A 30-Year Longitudinal Cohort Study

Grants

Funding Acknowledgements

Outside the submitted work, Dr Brodie serves on the scientific advisory boards of Eisai Ltd, UCB Pharma, GlaxoSmithKline, Lundbeck, Bial, GW Pharmaceuticals, and Takeda; is on the speakers' bureau for Eisai Ltd, UCB Pharma, GlaxoSmithKline, Lundbeck, Sanofi Aventis, and Abbott; and has accepted travel grants for scientific meetings from Eisai Ltd, UCB Pharma, and Lundbeck. Dr Liew has received research grants from the National Health and Medical Research Council of Australia, the Australian Research Council, and the National Heart Foundation of Australia. He and/or his institution has also received speaker or consultancy fees and/or research grants from Pfizer, AbbVie, Sanofi, AstraZeneca, GlaxoSmithKline, and Amgen. Dr Kwan has received research grants from the National Health and Medical Research Council of Australia, the Australian Research Council, the US National Institutes of Health, Hong Kong Research Grants Council, Innovation and Technology Fund, Health and Health Services Research Fund, and Health and Medical Research Fund. He and/or his institution also received speaker or consultancy fees and/or research grants from Eisai, GlaxoSmithKline, Johnson & Johnson, Pfizer, and UCB Pharma. No other disclosures are reported.